Drug intelligence / Profile preview

faecal microbiota transplant

Development stage: Unknown
Lead developer: University of Birmingham
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Rectal

Overview

This is an investigational faecal microbiota transplant (FMT) therapy being evaluated in the FARGO trial, a phase IIa randomized, placebo-controlled clinical trial. The therapy is led and manufactured by the University of Birmingham's Microbiome Treatment Centre. It consists of processed fecal material containing natural gut microbes from rigorously screened healthy donors. The treatment is being investigated for patients with non-cirrhotic primary sclerosing cholangitis (PSC) who also have concomitant inflammatory bowel disease (IBD). The biological target is the gut microbiome imbalance (dysbiosis) observed in these patients, with the aim of correcting it and potentially modulating immune pathways implicated in the disease's pathogenesis. The trial involves an initial dose via colonoscopy followed by seven weekly enemas.

Other names: faecal microbiota transplant-University of Birmingham-primary sclerosing cholangitis-inflammatory bowel diseaseFMT (FARGO trial)

Beyond the preview

Go deeper on faecal microbiota transplant.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on faecal microbiota transplant.

Explore the full profile